Oncoinvent ASA

Director's Dealing • Nov 3, 2025

NOTIFICATION BY PRIMARY INSIDERS/RELATED PARTIES TO ONCOINVENT ASA

1	Details of the Primary Insider/Related Party
a)	Name	Charles Gillies O'Bryan-Tear
2	Reason for the notification
a)	Position/status	Primary insider and chairperson of the board of directors
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	420,938
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 420,938 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Gro Elisabeth Hjellum
2	Reason for the notification
a)	Position/status	Primary insider and Chief Operating Officer
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	48,107
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 48,107 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Kristine Lofthus
2	Reason for the notification
a)	Position/status	Primary insider and Chief Production Officer
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	8,017
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 8,017 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Stian Brekke
2	Reason for the notification
a)	Position/status	Primary insider and Head of Regulatory Affairs
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	45,100
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 45,100 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Anne Cecilie Alvik
2	Reason for the notification
a)	Position/status	Primary insider and Head of Quality Assurance
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
	conducted
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	15,875
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 15,875 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Abakus Invest AS
2	Reason for the notification
a)	Position/status	Close associate to primary insider and Chief Executive Officer, Øystein Soug.
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	180,402
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 180,402 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Hadean Capital I AS
2	Reason for the notification
a)	Position/status	Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay.
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	10,621,231
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 10,621,231 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	HVentures Capital I AB
2	Reason for the notification
a)	Position/status	Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay.
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	4,817,485
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 4,817,485 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Teakay Invest AS
2	Reason for the notification
a)	Position/status	Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay.
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	297,187
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 297,187 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name	Itza AS
2	Reason for the notification
a)	Position/status	Close associate to primary insider and Chief Financial Officer, Tore Kvam.
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	72,160
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 72,160 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue

1	Details of the Primary Insider/Related Party
a)	Name K OG K AS
2	Reason for the notification
a)	Position/status	Grønås.	Close associate to primary insider and board member of the board of directors, Kari
b)	Initial notification/ Amendment	Initial notification
3	Details of the company
a)	Name	Oncoinvent ASA
b)	LEI	213800TYYFXKYF3V2A23
4		Details of the transaction(s): section to be repeated for (i) each type of instrument;
	conducted	(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	90,201
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 90,201 consideration shares for a total amount of NOK 0.
e)	Date of the transaction	2025-11-03
f)	Place of transaction	Outside a trading venue